Teva Q1 2023 Earnings: A Mix Of Challenges And Opportunities | Seeking Alpha
Biden admin urges Supreme Court to hear 'skinny labels' case between Teva, GSK | Reuters
Teva Settles Cephalon Generics Case With F.T.C. for $1.2 Billion - The New York Times
Teva Hit With New Lawsuit Over Proposed Korlym Drug Copy
Brussels' Teva probe reveals dark side of patent protections | Financial Times
US states accuse Teva and other drugmakers of colluding to inflate prices over 1,000%
Teva Settles Arkansas Price-Fixing Case for $931K | Arkansas Business News | ArkansasBusiness.com
20 States Accuse Generic Drug Companies of Price Fixing - The New York Times
Case studies in Strategy: Teva
Teva stocks fall after company said named in US price-fixing drug 'cartel' probe | The Times of Israel
Pfizer and Teva face new drug delay action - Global Competition Review
Teva must face government's kickback claims over Copaxone - judge | Reuters
Copaxone not dead yet as Teva appeal lives on | Evaluate
Update On The Teva Copaxone EU Case. The EU Commission Issues A Statement Of Objections Against Teva Over Alleged Anti-Competitive Conduct Consisting Of Misuse Of Divisional Patents And A Disparagement Campaign Against
Teva Is Easy Pill to Swallow - WSJ
Teva settles Cephalon case with FTC for $1.2 billion over sleep drug - The Boston Globe
Gilead, Teva and J&J's HIV antitrust case inches closer to trial
Teva neck-deep in legal trouble with no end in sight | Ctech
Gilead And Teva's HIV Antitrust Trial Begins
Antitrust: Commission fines Teva and Cephalon €60.5 million
Teva slide could draw vultures but it won't be easy prey | The Times of Israel
